Rheumatology Service, Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba, Reina Sofia University Hospital, Córdoba, Spain.
Front Immunol. 2024 Aug 7;15:1459185. doi: 10.3389/fimmu.2024.1459185. eCollection 2024.
Psoriatic disease, encompassing both psoriasis (Pso) and psoriatic arthritis (PsA), is closely intertwined with a significantly elevated risk of developing cardiovascular diseases. This connection is further compounded by a higher prevalence of cardiometabolic comorbidities, including type 2 diabetes, obesity, insulin resistance, arterial hypertension, and dysregulated lipid profiles. These comorbidities exceed the rates seen in the general population and compound the potential for increased mortality among those living with this condition. Recognizing the heightened cardiometabolic risk inherent in psoriatic disease necessitates a fundamental shift in the treatment paradigm. It is no longer sufficient to focus solely on mitigating inflammation. Instead, there is an urgent need to address and effectively manage the metabolic parameters that have a substantial impact on cardiovascular health. Within this context, apremilast emerges as a pivotal treatment option for psoriatic disease. What sets apremilast apart is its dual-action potential, addressing not only inflammation but also the critical metabolic parameters. This comprehensive treatment approach opens up new opportunities to improve the well-being of people living with psoriatic disease. This review delves into the multifaceted aspects involved in the development of cardiovascular disease and its intricate association with psoriatic disease. We then provide an in-depth exploration of the pleiotropic effects of apremilast, highlighting its potential to simultaneously mitigate metabolic complications and inflammation in individuals affected by these conditions.
银屑病疾病，包括银屑病（Pso）和银屑病关节炎（PsA），与心血管疾病的发病风险显著增加密切相关。这种关联因代谢合并症（包括 2 型糖尿病、肥胖、胰岛素抵抗、动脉高血压和脂质代谢紊乱）的高发率而更加复杂。这些合并症的发生率高于一般人群，增加了此类患者的死亡率。认识到银屑病疾病中存在的代谢风险需要彻底改变治疗模式。仅仅关注减轻炎症已经不够了。相反，迫切需要解决和有效管理对心血管健康有重大影响的代谢参数。在这种情况下，阿普米司特成为治疗银屑病疾病的关键选择。阿普米司特的独特之处在于其双重作用机制，不仅能减轻炎症，还能调节关键代谢参数。这种全面的治疗方法为改善银屑病患者的健康状况提供了新的机会。本综述深入探讨了心血管疾病发展及其与银屑病疾病复杂关联的多方面问题。然后，我们深入探讨了阿普米司特的多效性作用，强调了其在减轻这些疾病患者代谢并发症和炎症方面的潜力。
